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Abstract
Introduction Chronic obstructive pulmonary disease
(COPD) exacerbations are associated with systemic con-
sequences. Data from a 4-year trial (Understanding
Potential Long-term Impacts on Function with Tiotropium
[UPLIFT
], n = 5,992) were used to determine risk for
nonlower respiratory serious adverse events (NRSAEs)
following an exacerbation.
Methods Patients with C1 exacerbation were analyzed.
NRSAE incidence rates (incidence rate [IR], per 100
patient-years) were calculated for the 30 and 180 days
before and after the ﬁrst exacerbation. NRSAEs were
classiﬁed by diagnostic terms and organ classes. Maentel-
Haenszel rate ratios (RR) (pre- and postexacerbation onset)
along with 95% conﬁdence intervals (CI) were computed.
Results A total of 3,960 patients had an exacerbation. The
meanagewas65 years,forcedexpiratoryvolumein1 s(FEV1)
was 38% predicted, and 74% were men. For all NRSAEs, the
IRs 30 days before and after an exacerbation were 20.2 and
65.2 with RR (95% CI) = 3.22 (2.40–4.33). The IRs for the
180-day periods were 13.2 and 31.0 with RR (95% CI) = 2.36
(1.93–2.87). The most common NRSAEs by organ class for
both time periods were cardiac, respiratory system (other), and
gastrointestinal. All NRSAEs as well as cardiac events were
more common after the ﬁrst exacerbation, irrespective of
whether the patient had cardiac disease at baseline.
Conclusions The ﬁndings conﬁrm that, after exacerba-
tions, serious adverse events in other organ systems are
more frequent, particularly those that are cardiac in nature.
Keywords Chronic obstructive pulmonary disease 
Exacerbations  Morbidity  Clinical trials  Adverse events
Introduction
Exacerbations of chronic obstructive pulmonary disease
(COPD)impairhealthstatus[1,2]andappeartoacceleratethe
progression of the disease [3]. An exacerbation can lead to
profound symptoms, disrupt the abilityto engage in activities
of daily living, and may take several weeks or months to
resolve [4]. Of note, some patients may not fully return to
baseline function following an exacerbation of COPD.
Exacerbations are associated with a considerable early
mortality [5], but the frequency and severity of exacerba-
tions are also associated with long-term mortality, inde-
pendent of age, forced expiratory volume in 1 s (FEV1),
body mass index, and the presence of comorbidities [6].
Comorbidities are common in people with COPD, and they
may be worsened by the occurrence of an exacerbation and
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bation itself.
The Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFT
) trial was designed to
determine the long-term efﬁcacy and safety of tiotropium, a
once-daily, inhaled anticholinergic, in patients with COPD,
with the rate ofdecline inFEV1being theprimaryend point.
AlthoughtherewasnodifferenceintherateofFEV1decline
over the control group, patients receiving tiotropium had
signiﬁcantimprovementsinlungfunctionandhealth-related
quality of life and a reduced risk for exacerbations, associ-
ated hospitalizations, and episodes of respiratory failure, as
well as a reduced all-cause mortality [7].
Patients who participated in the UPLIFT
 study were
carefully observed over a period of 4 years, and the
occurrence of exacerbations and adverse events were
recorded throughout the period in which patients were
receiving the study drug. We therefore examined this large
clinical trial database to assess the relationship between
exacerbations and the occurrence of nonrespiratory mor-
bidity recorded as adverse events.
Methods
Details of the UPLIFT
 study design and results of the pri-
mary and secondary end points have been reported previ-
ously [7, 8]. All patients gave written informed consent, and
the study was approved by local ethical review boards and
conducted in accordance with the Declaration of Helsinki.
Study Design
The study was a 4-year, randomized, double-blind,
placebo-controlled, parallel-group trial of patients with
COPD. Patients received either tiotropium 18 lg once
daily or a matching placebo delivered via the HandiHaler

inhalation device (Boehringer Ingelheim International
GmbH, Ingelheim, Germany).
Patients were recruited from 490 investigational centers
in 37 countries. Criteria for participation included diag-
nosis of COPD, age at least 40 years, smoking history of at
least 10 pack-years, postbronchodilator FEV1 B70% of the
predicted normal, and FEV1 B70% of forced vital capacity.
Postrandomization clinic visits occurred at 1 and 3 months
and then every 3 months throughout the 4-year treatment
period. All respiratory medications, other than inhaled
anticholinergics, were permitted during the trial.
Exacerbations
Exacerbations were deﬁned as an increase in or the new
onset of more than one respiratory symptom (cough,
sputum, sputum purulence, wheezing, or dyspnea) lasting
3 days or more and requiring treatment with an antibiotic
or a systemic corticosteroid. Data regarding exacerbations
and related hospitalizations were collected on study-spe-
ciﬁc case-report forms at every visit.
Adverse Events
Adverse events, including those deemed serious and fatal,
were coded using the Medical Dictionary for Regulatory
Activities (MedDRA) ver. 11.1. Diagnostic terms are
referred to as preferred terms. These are totaled in higher
categories, including organ systems (referred to as system
organ classes [SOCs]). Additional prespeciﬁed categories
of preferred terms were also formed prior to unblinding of
the trial, where several preferred terms described a similar
clinical event. Because numerous categories exist, those
that are representative of major groupings and are of sig-
niﬁcant public health concern have been chosen for dis-
play. An individual patient may contribute several terms
but will be represented only once in a category, such as a
SOC.
Serious adverse events were identiﬁed according to the
standard deﬁnition: ‘‘A serious adverse event (experience)
or reaction is any untoward medical occurrence that at any
dose: results in death, is life-threatening, requires inpatient
hospitalization or prolongation of existing hospitalization,
results in persistent or signiﬁcant disability/incapacity, or is
a congenital anomaly/birth defect’’ [9].
Data Analysis
The population included in the current analysis was
restricted to only those patients with an exacerbation of
COPD. Only patients who survived their ﬁrst exacerbation
(i.e., the investigator indicated resolution of the exacerba-
tion prior to a fatal event, if present) were included in order
to determine the frequency of nonrespiratory events fol-
lowing the onset of an exacerbation.
Serious adverse event incidence rates (IRs) (per 100
patient-years) were calculated for time periods limited to
30 and 180 days before and after the ﬁrst recorded exac-
erbation (using a standardized deﬁnition). In patients who
had more than one exacerbation, the analysis was restricted
to before and after the ﬁrst exacerbation. IRs were calcu-
lated from the number of patients experiencing an event
divided by the person-years at risk. Maentel-Haenszel rate
ratios (RR) (pre- and postexacerbation onset) were com-
puted along with the associated 95% conﬁdence interval
(CI). Only people who remained exacerbation-free for at
least 30 or 180 days were included in the analyses. Events
occurring on the same day as the onset of the exacerbation
were included in the ‘‘after’’ period as they were
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123considered to be related to the occurrence of the exacer-
bation. The IRs and RRs for nonlower respiratory serious
adverse events (NRSAEs) were also calculated separately
for patients who did or did not have a cardiac disorder
present at entry into the study.
In order to examine the inﬂuence of season on the
relationship between exacerbations and subsequent adverse
events, the IRs and RRs before and after the ﬁrst exacer-
bation were calculated separately according to whether the
ﬁrst exacerbation occurred in the winter (October–March
for northern hemisphere countries and April–September for
southern hemisphere countries) or summer period. For this
analysis, each patient was included in the preexacerbation
period for as long as he/she did not experience an exac-
erbation or the occurrence of the respective adverse event.
Each patient was included in the postexacerbation period,
starting with the onset of the ﬁrst exacerbation and for as
long as they were in the study until 30 days after treatment
or the occurrence of the respective adverse event.
Results
Study Population
The UPLIFT
 population consisted of 5,992 randomized
patients who received the study drug (3,006 to placebo and
2,986 to tiotropium). The baseline demographics have been
previously reported [7]. The mean age was 65 ± 8 years,
75% of the patients were men, and 30% were smoking
at randomization. Mean prebronchodilator FEV1 was
1.10 ± 0.40 L (39% predicted) and postbronchodilator
FEV1 was 1.32 ± 0.44 L (48% predicted). Approximately
45% of the control population prematurely discontinued
placebo compared with 36% of patients treated with tiot-
ropium. At baseline, approximately 62% of patients used
an inhaled steroid, 60% used a long-acting b-agonist, and
23% used theophylline-containing preparations. Serious
adverse events were reported by 52% in the tiotropium
group and 50% in the placebo group [7]. Serious adverse
events reported by more than 1% of patients in either study
group were cardiac, respiratory, or neoplastic [7].
A total of 3,960 patients had a nonfatal exacerbation
during the 4-year follow-up period. Table 1 shows the
baseline characteristics of patients who had an exacerba-
tion. Serious adverse events were reported by 52% in the
tiotropium group and 50% in the placebo group [7].
The IRs (per 100 patient-years) and incidence RRs for
30 days before and after the ﬁrst exacerbation for the
NRSAEs by organ class where at least ﬁve people expe-
rienced an event are shown in Table 2 (sorted by the IR in
the postexacerbation period). The most common prespec-
iﬁed adverse event categories where at least ﬁve people
experienced the event during this time period are also listed
in Table 2. Cardiac disorders and gastrointestinal (GI)
disorders were the most commonly occurring serious
nonrespiratory adverse event organ classes. In all organ
classes, the RR (i.e., risk) of an event was higher after an
exacerbation. For ﬁve of these 13 organ classes affected,
the lower limits of the 95% CI exceeded ‘‘1.’’ Cardiac
failure, ischemic heart disease, myocardial infarction (MI),
angina, atrial ﬁbrillation/ﬂutter, and stroke were the most
common prespeciﬁed events overall. For all nine of the
categories, the risk of an event was again higher after an
exacerbation, and for four of these categories (all cardiac),
the lower limits of the 95% CI for the RR exceeded ‘‘1.’’
The IRs (per 100 patient-years) and incidence RRs for
180 days before and after the ﬁrst exacerbation for the
NRSAEs by organ class where at least 10 people experi-
enced an event during the period are shown in Table 3
(sorted by the IR in the postexacerbation period). Cardiac
disorders and GI disorders were again the most commonly
occurring serious nonrespiratory adverse event organ
classes. In all organ classes, the risk of an event was higher
after an exacerbation. For seven of these 11 organ classes
Table 1 Baseline characteristics of patients who had an exacerbation
(N = 3,960)
Age (years) 64 (8)
Male (%) 74
Prebronchodilator FEV1 (L) 1.07 (0.39)
Postbronchodilator FEV1 (L) 1.29 (0.43)
Prebronchodilator FEV1 (% predicted) 38 (12)
Postbronchodilator FEV1 (% predicted) 47 (13)
Prebronchodilator FVC (L) 2.60 (0.81)
FEV1/FVC 0.42 (0.10)
GOLD stage (%)
II 43
III 46
IV 9
BMI (kg/m
2) 26 (5)
Current smokers (%) 29
Smoking history (pack-years) 49 (28)
COPD duration (years) 10 (7)
Baseline LABA (%) 64
Baseline ICS (%) 65
Baseline ICS ? LABA (%) 53
Baseline anticholinergic (%) 46
SGRQ total score, units 47 (17)
Data are mean (SD) (where shown)
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity,
GOLD Global Initiative for Chronic Obstructive Lung Disease, BMI
body mass index, COPD chronic obstructive pulmonary disease,
LABA long-acting b-agonist, ICS inhaled corticosteroid, SGRQ
St. George’s Respiratory Questionnaire
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123affected, the lower limits of the 95% CI for the RR
exceeded ‘‘1.’’ Cardiac failure, ischemic heart disease, MI,
angina, atrial ﬁbrillation/ﬂutter, and stroke were again the
most common prespeciﬁed events overall. For all six of the
common events, the risk of an event was higher after an
exacerbation, and for ﬁve of these categories (all cardiac),
the lower limits of the 95% CI for the RR exceeded ‘‘1.’’
The IRs and RRs for NRSAEs in the 30 and 180 days
before and after the ﬁrst exacerbation according to whether
patients did or did not have a cardiac disorder present at
entry to the study are shown in Tables 4 and 5. Overall
serious adverse events were more common in people who
had cardiac disease at baseline. Ischemic heart disease, MI,
angina, cardiac failure, atrial ﬁbrillation/ﬂutter, nonven-
tricular tachycardia, and stroke were all more common in
the 30- and 180-day periods after an exacerbation than
before, irrespective of the presence of cardiac disease at
baseline. In people who did not have cardiac disease at
entry to the study, the lower limits of the 95% CI exceeded
‘‘1’’ only for ischemic heart disease and cardiac failure for
the 30-day period and for ischemic heart disease, MI,
angina, and cardiac failure for the 180-day period.
The IRs and RRs before and after the ﬁrst exacerbation
for ﬁrst exacerbations that occurred in the winter and
Table 2 IRs and RRs 30 days before and after the ﬁrst exacerbation for the most common NRSAEs by SOC and prespeciﬁed adverse event
category (N C 5 in either category) (N = 3,512 for patients in the analysis)
Before exacerbation After exacerbation Incidence RR (95% CI)
N IR
a N IR
a
SOC
Total 58 20.2 181 65.2 3.22 (2.40–4.33)
Cardiac 8 2.78 75 26.4 9.52 (4.59–19.7)
Respiratory system (other)
b 6 2.08 28 9.77 4.69 (1.94–11.3)
Gastrointestinal 15 5.21 18 6.26 1.20 (0.61–2.39)
General and administration site
c 5 1.73 14 4.86 2.80 (1.01–7.79)
Nervous system 7 2.43 14 4.87 2.00 (0.81–4.96)
Infections and infestations
d 2 0.69 13 4.52 6.51 (1.47–28.9)
Vascular 0 0 12 4.17 NE
Respiratory system (upper)
b 2 0.69 10 3.48 5.01 (1.10–22.9)
Neoplasms (not lung)
d 3 1.04 6 2.08 2.00 (0.50–8.00)
Psychiatric disorders 3 1.04 6 2.08 2.00 (0.50–8.00)
Metabolism and nutrition 3 1.04 6 2.08 2.00 (0.50–8.00)
Injury, poisoning, procedural 2 0.69 5 1.73 2.50 (0.49–12.9)
Renal and urinary 2 0.69 5 1.73 2.50 (0.49–2.9)
Prespeciﬁed adverse event category
Cardiac failure 2 0.69 28 9.77 14.08 (3.36–59.1)
Ischemic heart disease 5 1.73 23 8.01 4.62 (1.76–12.2)
Atrial ﬁbrillation/ﬂutter 1 0.35 17 5.92 17.06 (2.27–128)
MI 1 0.35 13 4.52 13.04 (1.71–99.7)
Angina 4 1.39 11 3.82 2.75 (0.88–8.65)
Stroke 2 0.69 9 3.12 4.51 (0.97–20.86)
Upper respiratory tract infection 1 0.35 7 2.43 7.01 (0.86–57.00)
Non-ventricular tachycardia, including SVT 0 0 7 2.43 NE
Body temperature increased 2 0.69 6 2.08 3.00 (0.61–14.87)
IR incidence rate, RR rate ratio (after/before), NRSAE nonlower respiratory serious adverse event, CI conﬁdence interval, SOC system organ
class, NE not estimable as pre-exacerbation IR = 0, MI myocardial infarction, SVT supraventricular tachycardia, MedDRA Medical Dictionary
for Regulatory Activities
a IR per 100 patient-years
b All primary SOCs are deﬁned by MedDRA with the exception of ‘‘Respiratory, thoracic, and mediastinal disorders,’’ which has been divided
into separate classes of respiratory system disorders: Lower, Upper, and Other
c SOC ‘‘General disorders and administration site conditions’’ includes the cardiac preferred terms chest discomfort, chest pain, edema
peripheral, sudden death, edema due to cardiac disease, and cardiac death
d Preferred terms with a secondary relationship to MedDRA SOC respiratory, thoracic, and mediastinal disorders are not included
264 Lung (2011) 189:261–268
123summer periods are shown in Table 6. The CIs of the RRs
(before/after an exacerbation) for the two periods over-
lapped, indicating that the relationship between adverse
events and exacerbations did not differ according to whe-
ther the exacerbation occurred in the summer or winter.
Discussion
The UPLIFT
 trial was designed to assess the effect of
tiotropium on the clinical course of patients with COPD
who were permitted to use all respiratory medications
throughout the trial, other than inhaled anticholinergics.
The study showed that use of tiotropium was associated
with improvements in lung function and quality of life and
a reduction of 14% in the risk for an exacerbation
(p\0.001) [7]. The incidence of serious adverse events
was also lower in patients receiving tiotropium.
In addition to providing data on the clinical effects of
tiotropium, the UPLIFT
 study provided information on
the relationship between exacerbations and NRSAEs. The
results of this analysis show that exacerbations were
associated with an increased risk of serious events in other
organ systems, most commonly cardiac. This was true in
both patients treated with tiotropium and those receiving
the placebo in addition to their usual medication, and in
patients who did or did not have cardiac disease at entry to
the study.
A previous smaller observational study of the temporal
relationship between exacerbations and cardiovascular
events using the Health Improvement Network database
suggested a 2.3-fold increase in the risk of a MI 1-5 days
after an exacerbation; however, there did not appear to be
an association at any other time following an exacerbation.
The risk for stroke was increased by 1.3-fold within
1-49 days following an exacerbation [10].
Table 3 IRs and RRs 180 days before and after the ﬁrst exacerbation for the most common NRSAEs by SOC and prespeciﬁed adverse event
category (N C 10 in either category) (N = 2,289 for patients in the analysis)
Before exacerbation After exacerbation Incidence RR (95% CI)
N IR
a N IR
a
SOC
Total 144 13.2 304 31.0 2.36 (1.93–2.87)
Cardiac 28 2.50 104 10.1 4.03 (2.65–6.11)
Respiratory system (other)
b 8 0.71 48 4.57 6.43 (3.04–13.6)
Gastrointestinal 25 2.23 35 3.32 1.49 (0.89–2.49)
Neoplasms (not lung)
c 23 2.05 28 2.65 1.29 (0.74–2.24)
Vascular 9 0.80 26 2.46 3.08 (1.44–6.56)
Infections and infestations
c 10 0.89 24 2.27 2.55 (1.22–5.34)
Nervous system 13 1.15 23 2.18 1.89 (0.95–3.72)
General and administration site
d 8 0.71 22 2.08 2.93 (1.30–6.58)
Renal and urinary 5 0.44 14 1.32 2.98 (1.07–8.27)
Injury, poisoning, procedural 10 0.89 13 1.23 1.38 (0.61–3.15)
Metabolism and nutrition 2 0.18 10 0.94 5.32 (1.17–24.3)
Prespeciﬁed adverse event category
Cardiac failure 4 0.35 40 3.80 10.71 (3.83–29.9)
Ischemic heart disease 12 1.07 32 3.04 2.85 (1.47–5.54)
Atrial ﬁbrillation/ﬂutter 4 0.36 25 2.37 6.66 (2.32–19.14)
Angina 7 0.62 20 1.89 3.05 (1.29–7.20)
MI 5 0.44 15 1.42 3.20 (1.16–8.79)
Stroke 6 0.53 13 1.23 2.31 (0.88–6.06)
IR incidence rate, RR rate ratio (after/before), NRSAE nonlower respiratory serious adverse event, SOC system organ class, CI conﬁdence
interval, MI myocardial infarction, MedDRA Medical Dictionary for Regulatory Activities
a IR per 100 patient-years
b All primary system organ classes are deﬁned by MedDRA with the exception of ‘‘Respiratory, thoracic, and mediastinal disorders,’’ which has
been divided into separate classes of respiratory system disorders: Lower, Upper, and Other
c Preferred terms with a secondary relationship to MedDRA SOC respiratory, thoracic, and mediastinal disorders are not included
d SOC ‘‘General disorders and administration site conditions’’ includes the cardiac preferred terms chest discomfort, chest pain, edema
peripheral, sudden death, edema due to cardiac disease, and cardiac death
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123Exacerbations may be triggered by bacteria, viruses, and
noninfective stimuli such as air pollution. These stimuli
appear to amplify the inﬂammatory process present in the
stable state [11]. Exacerbations increase the level of sys-
temic inﬂammation [12, 13] and oxidative stress [14, 15],
which can have adverse effects on other organs. For
example, troponin T is elevated during exacerbations and is
associated with increased mortality [16]. Similarly, renal
endothelin-1 production is increased during exacerbations
[17], which may underpin some of the vascular conse-
quences of exacerbations. There is an increased
prothrombotic state in patients with COPD during acute
exacerbations, as shown by increased circulating ﬁbrinogen
levels [12], and there is evidence of increased endothelial
dysfunction during and after exacerbations of COPD [18],
increasing the risk of cardiovascular morbidity.
It is also possible that the factors that lead to exacer-
bations may also have systemic consequences. MIs, pul-
monary emboli, and venous thromboses are signiﬁcantly
more common immediately after respiratory infections
[19], which are associated with peripheral acute-phase
responses, including the production and release of TNF-a,
Table 4 IRs and RRs 30 days before and after the ﬁrst exacerbation for cardiovascular NRSAEs by selected prespeciﬁed adverse event category
according to presence or absence of cardiac disorders at baseline
Prespeciﬁed adverse event category
a Cardiac disorder present at baseline (N = 917) Cardiac disorder absent at baseline (N = 2,595)
Before
exacerbation
After
exacerbation
Incidence RR
(95% CI)
Before
exacerbation
After
exacerbation
Incidence RR
(95% CI)
N IR
b N IR
b N IR
b N IR
b
All 27 36.3 68 95.4 2.63 (1.68–4.11) 31 14.6 113 54.8 3.75 (2.52–5.58)
Ischemic heart disease 3 3.99 10 13.4 3.36 (0.92–12.2) 2 0.94 13 6.12 6.52 (1.47–28.9)
MI 1 1.33 5 6.67 5.02 (0.59–43.0) 0 0 8 3.76 NE
Angina 2 2.66 5 6.67 2.51 (0.49–12.9) 2 0.94 6 2.82 3.00 (0.61–14.9)
Cardiac failure 1 1.33 12 16.1 12.1 (1.58–93.2) 1 0.47 16 7.54 16.1 (2.13–121)
Atrial ﬁbrillation/ﬂutter 1 1.33 10 13.4 10.1 (1.29–78.8) 0 0 7 3.29 NE
Nonventricular tachycardia, including SVT 0 0 3 3.99 NE 0 0 4 1.88 NE
Stroke 0 0 3 3.99 NE 2 0.94 6 2.82 3.00 (0.61–14.9)
IR incidence rate, RR rate ratio (after/before), NRSAE nonlower respiratory serious adverse event, CI conﬁdence interval, MI myocardial
infarction, NE not estimable as pre-exacerbation IR = 0, SVT supraventricular tachycardia, MedDRA Medical Dictionary for Regulatory
Activities
a Preferred terms with a secondary relationship to MedDRA SOC
b IR per 100 patient-years
Table 5 IRs and RRs 180 days before and after the ﬁrst exacerbation for cardiovascular NRSAEs by selected prespeciﬁed adverse event
category according to presence or absence of cardiac disorders at baseline
Prespeciﬁed adverse event category
a Cardiac disorder present at baseline (N = 578) Cardiac disorder absent at baseline (N = 1,711)
Before
exacerbation
After
exacerbation
Incidence RR
(95% CI)
Before
exacerbation
After
exacerbation
Incidence RR
(95% CI)
N IR
b N IR
b N IR
b N IR
b
All 60 22.3 112 46.9 2.11 (1.54–2.88) 84 10.2 192 25.9 2.54 (1.97–3.28)
Ischemic heart disease 8 2.82 16 6.05 2.14 (0.92–5.01) 4 0.47 16 2.03 4.28 (1.43–12.8)
MI 3 1.05 6 2.24 2.13 (0.53–8.51) 2 0.24 9 1.14 4.80 (1.04–22.2)
Angina 5 1.76 11 4.12 2.34 (0.81–6.73) 2 0.24 9 1.14 4.80 (1.04–22.2)
Cardiac failure 3 1.06 19 7.17 6.79 (2.01–22.9) 1 0.12 21 2.67 22.5 (3.02–167)
Atrial ﬁbrillation/ﬂutter 2 0.70 18 6.78 9.62 (2.23–41.5) 2 0.24 7 0.88 3.73 (0.77–17.9)
Nonventricular tachycardia, including SVT 1 0.35 2 0.74 2.12 (0.19–23.3) 2 0.24 5 0.63 2.66 (0.52–13.7)
Stroke 3 1.06 5 1.86 1.76 (0.42–7.38) 3 0.36 8 1.01 2.84 (0.75–10.7)
IR incidence rate, RR rate ratio (after/before), NRSAE nonlower respiratory serious adverse event, CI conﬁdence interval, MI myocardial
infarction, SVT supraventricular tachycardia, MedDRA Medical Dictionary for Regulatory Activities
a Preferred terms with a secondary relationship to MedDRA SOC
b IR per 100 patient-years
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123IL-6, and CRP. Particulate air pollution may also trigger a
systemic inﬂammatory response by inducing oxidative
stress in the airways [20].
In addition to the fact that exacerbations may worsen the
systemic effects of COPD, the presence of systemic effects
or comorbidities may also worsen the severity of an
exacerbation and lead to worse outcomes. In order to study
the effect of exacerbations on these effects it is important
to have prospective data from large cohorts such as the
UPLIFT
 trial. The data provide important evidence for
the relationship between exacerbations and serious nonre-
spiratory outcomes, although they cannot prove causality.
The conclusions are strengthened by the duration of the
study and the use of a standardized deﬁnition of an exac-
erbation. Nevertheless, there are still some potential limi-
tations to the analysis. It could be argued that the patients
who took part were selected for involvement in a clinical
trial and therefore may not be fully representative of
patients seen in practice, particularly with regard to disease
severity and the presence of comorbidities. However, the
inclusion and exclusion criteria were relatively liberal and
recruitment included a broad selection of COPD patients
with multiple comorbidities.
Time-based analyses are potentially subject to biases,
such as the need to survive long enough to be included in
the analysis, and these need to be considered when inter-
preting the results. Events occurring on the same day as the
onset of the exacerbation were included in the ‘‘after’’ and,
although it is possible that the adverse event in the other
organ system triggered the COPD exacerbation, we believe
that it is unlikely from a clinical perspective that an
exacerbation would be regarded as starting on the same
day. It is more likely it would be reported as starting after
the nonrespiratory adverse event.
Another possible confounder is the potential for detec-
tion bias as a result of additional tests being ordered as part
of an evaluation for an exacerbation or the possibility that
other medical conditions are identiﬁed when the patients
are admitted to hospital with an exacerbation. These factors
are likely to have only a limited role given that the current
analysis is based on serious adverse events and not con-
comitant nonserious events that may be incidental ﬁndings
as part of a broader medical evaluation. The frequency of
hospitalization is too low to allow a meaningful analysis of
differences in the occurrence of adverse events after hos-
pitalized and nonhospitalized exacerbations. Finally, it is
also possible that the treatment given to the patient at the
time of the exacerbation may have led to the development
of the adverse event.
In addition to the difﬁculty of proving a causal link,
there are other limitations to the analysis of the relationship
between exacerbations and systemic effects. To be recor-
ded as a serious adverse event, the systemic effect must
lead to death or be judged life-threatening, have required
inpatient hospitalization or prolongation of existing hos-
pitalization, or result in persistent or signiﬁcant disability/
Table 6 Patients with serious adverse events (other than lower respiratory tract disorders) before and after the ﬁrst exacerbation in summer and
winter—incidence RRs (after/before) adjusted for time at risk by SOC
SOC Summer (N = 1,535) Winter (N = 2,425)
All 1.39 (1.17–1.64) 1.75 (1.52–2.02)
Cardiac 2.12 (1.46–3.08) 2.06 (1.55–2.74)
Gastrointestinal 0.95 (0.63–1.43) 1.76 (1.20–2.58)
General and administration site
a 1.46 (0.81–2.65) 2.62 (1.57–4.39)
Infections and infestations
b 1.92 (1.06–3.51) 2.12 (1.33–3.40)
Injury, poisoning, procedural 2.37 (1.17–4.81) 1.63 (1.02–2.58)
Metabolism and nutrition 1.25 (0.56–2.78) 1.51 (0.68–3.32)
Neoplasms (not lung)
b 1.45 (0.94–2.24) 1.34 (0.94–1.91)
Nervous system 1.10 (0.67–1.82) 1.75 (1.13–2.72)
Renal and urinary 3.64 (1.30–10.3) 1.60 (0.85–3.04)
Respiratory system (other)
c 2.35 (1.24–4.47) 3.58 (2.19–5.84)
Respiratory system (upper)
c 1.41 (0.52–3.83) 2.02 (0.94–4.34)
Vascular 2.44 (1.15–5.17) 2.05 (1.25–3.36)
Values are incidence RR (95% CI)
RR rate ratio (after/before), SOC system organ class, CI conﬁdence interval, MedDRA Medical Dictionary for Regulatory Activities
a SOC ‘‘General disorders and administration site conditions’’ includes the cardiac preferred terms chest discomfort, chest pain, edema
peripheral, sudden death, edema due to cardiac disease, and cardiac death
b Preferred terms with a secondary relationship to MedDRA SOC respiratory, thoracic, and mediastinal disorders are not included
c All primary system organ classes are deﬁned by MedDRA with the exception of ‘‘Respiratory, thoracic, and mediastinal disorders,’’ which has
been divided into separate classes of respiratory system disorders: Lower, Upper, and Other
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123incapacity. While this could be considered restrictive, the
advantage is that only the most clinically important events
are part of the deﬁnition.
In conclusion, this analysis conﬁrms that besides wors-
ening respiratory outcomes, the risk of systemic events is
increased after exacerbations, particularly shortly after the
event. It further reinforces the importance of preventing or
reducing exacerbation rates as an aim of COPD manage-
ment. Treating physicians must also be vigilant for con-
comitant disease in other organ systems which may follow
an exacerbation. Increased awareness and prompt treatment
may contribute to reductions in morbidity associated with
COPD.
Acknowledgments We gratefully acknowledge the statistical help
provided by Dr. Dacheng Liu (Boehringer Ingelheim) and the edito-
rial support of Natalie Dennis (PAREXEL).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Spencer S, Jones PW (2003) Time course of recovery of health
status following an infective exacerbation of chronic bronchitis.
Thorax 58:589–593
2. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ,
Wedzicha JA (1998) Effect of exacerbation on quality of life in
patients with chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 157(5 Pt 1):1418–1422
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA
(2002) Relationship between exacerbation frequency and lung
function decline in chronic obstructive pulmonary disease. Tho-
rax 57:847–852
4. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wed-
zicha JA (2000) Time course and recovery of exacerbations in
patients with chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 161:1608–1613
5. Price LC, Lowe D, Hosker HS, Anstey K, Pearson MG, Roberts
CM, British Thoracic Society and the Royal College of Physi-
cians Clinical Effectiveness Evaluation Unit (CEEu) (2006) UK
National COPD Audit 2003: impact of hospital resources and
organisation of care on patient outcome following admission for
acute COPD exacerbation. Thorax 61:837–842
6. Soler-Catalun ˜a JJ, Martı ´nez-Garcı ´a MA, Roma ´nS a ´nchez P,
Salcedo E, Navarro M, Ochando R (2005) Severe acute
exacerbations and mortality in patients with chronic obstructive
pulmonary disease. Thorax 60:925–931
7. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S,
Decramer M, UPLIFT Study Investigators (2008) A 4-year trial
of tiotropium in chronic obstructive pulmonary disease. N Engl J
Med 359:1543–1554
8. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D,
Cassino C, Kesten S (2004) Clinical trial design considerations in
assessing long-term functional impacts of tiotropium in COPD:
the UPLIFT trial. COPD 1:303–312
9. International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use
(1994) Clinical safety data management: deﬁnitions and stan-
dards for expedited reporting E2A
10. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA
(2010) Increased risk of myocardial infarction and stroke fol-
lowing exacerbation of COPD. Chest 137:1091–1097
11. Celli BR, Barnes PJ (2007) Exacerbations of chronic obstructive
pulmonary disease. Eur Respir J 29:1224–1238
12. Wedzicha JA, Seemungal TA, MacCallum PK et al (2000) Acute
exacerbations of chronic obstructive pulmonary disease are
accompanied by elevations of plasma ﬁbrinogen and serum IL-6
levels. Thromb Haemost 84:210–215
13. Seemungal T, Harper-Owen R, Bhowmik A et al (2001) Respi-
ratory viruses, symptoms, and inﬂammatory markers in acute
exacerbations and stable chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 164:1618–1623
14. Rahman I, Skwarska E, MacNee W (1997) Attenuation of oxi-
dant/antioxidant imbalance during treatment of exacerbations of
chronic obstructive pulmonary disease. Thorax 52:565–568
15. Drost EM, Skwarski KM, Sauleda J et al (2005) Oxidative stress
and airway inﬂammation in severe exacerbations of COPD.
Thorax 60:293–300
16. Brekke PH, Omland T, Holmedal SH, Smith P, Søyseth V (2008)
Troponin T elevation and long-term mortality after chronic
obstructive pulmonary disease exacerbation. Eur Respir J 31:
563–570
17. Soﬁa M, Maniscalco M, Celentano L et al (2001) Abnormalities
of renal endothelin during acute exacerbation in chronic
obstructive pulmonary disease. Pulm Pharmacol Ther 14:
321–327
18. Ozben B, Eryu ¨ksel E, Tanrikulu AM, Papila-Topal N, Celikel T,
Bas ¸aran Y (2010) Acute exacerbation impairs endothelial func-
tion in patients with chronic obstructive pulmonary disease. Turk
Kardiyol Dern Ars 38:1–7
19. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P
(2006) Risk of deep vein thrombosis and pulmonary embolism
after acute infection in a community setting. Lancet 367:
1075–1079
20. Gilmour PS, Rahman I, Donaldson K, MacNee W (2003) Histone
acetylation regulates epithelial IL-8 release mediated by oxida-
tive stress from environmental particles. Am J Physiol Lung Cell
Mol Physiol 284:L533–L540
268 Lung (2011) 189:261–268
123